Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat and Temsirolimus in Pediatric DIPG
NCT02420613Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2015
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of temsirolimus in diffuse intrinsic pontine glioma (DIPG) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Maximum Tolerated Dose of Temsirolimus at 28 days, Incidence of Toxic Death up to 12 months and 1 more. Started Oct 2015; status: completed.
02
Drugs
temsirolimus
03
Conditions
diffuse intrinsic pontine glioma (DIPG)
Beyond the preview
Go deeper on NCT02420613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02420613.